Misuse of Pregabalin and Gabapentin: A Second Systematic Review Update
Open Access
- 3 June 2026
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 86 (8) , 1365-1378
Abstract
A 2017 systematic review and 2021 update identified 114 studies regarding gabapentinoid (gabapentin and pregabalin) misuse, dependence, or overdose. We aimed to update previous systematic reviews and describe new insights regarding gabapentinoid misuse. PubMed was searched from 1 September, 2020 to 24 January, 2025 using the following four searches: "gabapentin [MeSH] OR pregabalin [MeSH] OR gabapentinoid AND" one of the following four substance misuse-related terms: "substance-related disorders [MeSH]," "overdose," "abuse," or "misuse." Additional research was identified by reviewing papers cited by included studies. Studies presenting novel data regarding gabapentinoid misuse, dependence, or overdose were included. Non-English articles, review articles, and animal studies were excluded. One hundred studies (87 observational, 13 case reports/series) were included, from North America (33), Europe (39), Asia (20), Australia (7), and Africa (1). Sixteen studied gabapentin, 20 pregabalin, and 51 both medications. These studies corroborated previous findings that gabapentinoids are misused both for therapeutic and non-therapeutic purposes, often in conjunction with opioids or other substances, and commonly in people with substance use disorders and psychiatric conditions. Recent research built on the previous systematic review, providing more robust evidence that concomitant use with opioids or benzodiazepines increases overdose risks. New studies also highlight a growing body of evidence regarding misuse within the Middle East and North Africa, among adolescents, and in patients with chronic pain. Newly published evidence demonstrated that gabapentinoid misuse remains a significant concern, including in several populations not often highlighted in previous research. It provides more compelling evidence that gabapentinoids increase overdose risk, particularly when used with opioids or benzodiazepines.Keywords
This publication has 105 references indexed in Scilit:
- Buprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in FinlandInternational journal of legal medicine, 2024
- Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use DisorderJAMA Psychiatry, 2023
- Gabapentin withdrawal masquerading with stroke‐like symptomsPM&R, 2023
- Rescheduling gabapentinoids had negligible effects on prescribing behaviour by general practitioners in EnglandPharmacoepidemiology and Drug Safety, 2023
- Identifying Clinically Relevant Drug–Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal DetectionClinical Pharmacology & Therapeutics, 2022
- Misuse of prescribed psychotropic medication and drug crime offending: A follow‐up case‐control study of former adolescent psychiatric inpatientsCriminal Behaviour and Mental Health, 2022
- The impact of regulatory restrictions on pregabalin use in Saudi Arabia: An interrupted time series analysisPharmacoepidemiology and Drug Safety, 2022
- How prevalent and severe is addiction on GABAmimetic drugs in an elderly German general hospital population? Focus on gabapentinoids, benzodiazepines, and z‐hypnotic drugsHuman Psychopharmacology: Clinical and Experimental, 2021
- Pregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: A case series and literature reviewNeuropsychopharmacology Reports, 2021
- Coprescription of Opioids With Other Medications and Risk of Opioid OverdoseClinical Pharmacology & Therapeutics, 2021